CLDI — Calidi Biotherapeutics Income Statement
0.000.00%
Last trade - 00:00- $16.67m
- $11.50m
Annual income statement for Calidi Biotherapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | PROSPECTUS | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 0.449 | 0.045 | 0 | 0 |
| Cost of Revenue | |||||
| Gross Profit | 0 | 0.355 | 0.031 | 0 | — |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 6.72 | 11 | 23.2 | 29.5 | 21.8 |
| Operating Profit | -6.72 | -10.5 | -23.1 | -29.5 | -21.8 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -7.93 | -10.9 | -25.4 | -29.2 | -22.2 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -7.94 | -10.9 | -25.4 | -29.2 | -22.2 |
| Minority Interest | |||||
| Net Income Before Extraordinary Items | |||||
| Net Income | -7.94 | -10.9 | -25.4 | -29.2 | -22.1 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -7.94 | -10.9 | -25.4 | -29.2 | -23.8 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -1.75 | -2.4 | -5.59 | -5.4 | -2.97 |